Palvella Therapeutics (PVLA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.70
- Estimate
- -$1.73
- Surprise
- +1.8%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Palvella Therapeutics (PVLA) reported a narrower loss than forecast — adjusted EPS of -$1.70 against the -$1.73 estimate (a 1.8% beat on a still-unprofitable quarter).
Coverage in the report window
- Oppenheimer Adjusts Palvella Therapeutics Price Target to $232 From $210 — fiscal.ai, 2026-11-06
- Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232 — benzinga, 2026-11-06
- Palvella Therapeutics Q3 2026 Earnings Call Transcript — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates PVLA Sell at 5.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +1.8% surprise compares with a -19.5% four-quarter average. Next scheduled report: 2027-03-31.
What argues against it
- Concentration risk — Pipeline: QTORIN rapamycin
- Quality below floor (1.6 < 4.0)
- Reward/Risk 1.1:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $175.92
- Price target
- $205.56
- Stop
- $163.61
- Upside to target
- +16.8%
- Reward-to-risk
- 1.1:1
Risk check: RSI 84 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
PVLA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.53B
- P/E (fwd)
- -22.3
- 52-week range
- $72.22–$176.59
- Off 52-week high
- 0.4%
- RSI (14)
- 84
- Volume vs avg
- 1.85×
- Score today
- 5.3/10